All In Biotech

Drug Trial Radar · NCT05117242

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

125

Actual

Start

Oct 27, 2021

Primary completion

Dec 2, 2024

Study completion Aug 31, 2026

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug (pembrolizumab) for participants with relapsed/refractory (disease has returned after treatment or did not respond to treatment) non-small cell lung cancer (NSCLC; the most common type of lung cancer). This trial has 2 parts. The purpose of the first part is to find out if the combination of acasunlimab and pembrolizumab is safe and to find out the best doses to use. The purpose of the second part is to give acasunlimab and pembrolizumab to more participants to evaluate efficacy. In the second part of the trial, participants will be randomized to participate in 1 of the 3 arms of the trial. Randomized means that the participant will be randomly assigned to a treatment arm based on chance; no one chooses their treatment arm. Participants will receive either acasunlimab alone (100 followed by 500 mg into the vein) or acasunlimab with pembrolizumab (200 or 400 mg into the vein) once every 3 or 6 weeks, depending on which arm the participant is randomized into. All participants will receive active drug; no one will receive placebo. Trial details include: * The average trial duration for an individual participant will be about 10 months. * The average treatment duration for an individual participant will be about 6 months. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.

Conditions

  • Non Small Cell Lung Cancer Metastatic

Interventions

  • AcasunlimabBiological

    Acasunlimab will be administered intravenously (IV)

  • PembrolizumabBiological

    Pembrolizumab will be administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From first treatment to approximately 27 weeks after last subject's first dose

Locations

40 sites in 9 countries. Site status is shown where the registry gives one.

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • Florida Cancer Specialists - FCS South

    Fort Myers, Florida

  • Florida Cancer Center

    St. Petersburg, Florida

  • Henry Ford Cancer Institute

    Detroit, Michigan

  • Cancer & Hematology Centers of Western Michigan CHCWM P.C.

    Grand Rapids, Michigan

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Institut Bergonie

    Bordeaux, France

  • Hopital Morvan CHU de Brest

    Brest, France

  • Hopital Charles Nicolle Chu Rouen

    Rouen, France

  • Hopital dInstruction Des Armees Begin

    Saint-Mandé, France

  • Institut de Cancerologie Strasbourg Europe (ICANS)

    Strasbourg, France

  • Hôpital Foch

    Suresnes, France

  • Gustave Roussy

    Villejuif, France

  • Med.Hochschule Hannover Klinik für Pneumologie

    Hanover, Germany

  • Universitatsklinik Giessen und Marburg Standort Giessen

    Hessen, Germany

  • LKI Lungenfachklinik Immenhausen

    Immenhausen, Germany

  • Department of Internal Medicine II

    Regensburg, Germany

  • Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco

    Catania, Italy

  • IRCCS Istituto Europeo di Oncologia

    Milan, Italy

  • UOC Oncoematologia AOU L.Vanvitelli

    Naples, Italy

  • La Maddalena SPA

    Palermo, Italy

  • IFO Regina Elena

    Roma, Italy

  • Netherlands Cancer Institute

    Amsterdam, Netherlands

  • VU University Medical Center

    Amsterdam, Netherlands

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

    Olsztyn, Poland

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Centro Clinico Champalimaud

    Lisbon, Portugal

  • Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio

    Porto, Portugal

  • Hospital Universitari Vall dHebron

    Barcelona, Spain

  • Clinica Universidad de Navarra CUN

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Fundacion Instituto Valenciano de Oncologia

    Valencia, Spain

  • Cheltenham General Hospital

    Cheltenham, United Kingdom

  • The Christie Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.